

Freedom of Information Request	FOI 21-403	13 <sup>th</sup> October 2021
--------------------------------	------------	-------------------------------

**1. Could you please provide the numbers of patients treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs**

- **Adalimumab - Humira**
- **Adalimumab Biosimilar**
- **Apremilast**
- **Bimekizumab**
- **Brodalumab**
- **Certolizumab**
- **Dimethyl fumarate**
- **Etanercept - Enbrel**
- **Etanercept Biosimilar**
- **Guselkumab**
- **Infliximab - Remicade**
- **Infliximab Biosimilar**
- **Ixekizumab**
- **Risankizumab**
- **Secukinumab**
- **Tildrakizumab**
- **Ustekinumab**

Please see spreadsheet attached.

**Q2. How many patients have been treated for Psoriasis ONLY in the last three months with the following:**

- **Ciclosporin**
- **Methotrexate - any form and strength**
- **Methotrexate injections 15mg and above**

Dermatology are not currently treating any patients with Ciclosporin.

There is approximately 100 patients in dermatology being treated with Methotrexate. Unfortunately, we do not hold a database of the doses or method in which Methotrexate is prescribed, nor if it is used to treat Psoriasis or Eczema.